Status:
TERMINATED
Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Axial Spondyloarthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare selective cyclooxygenase-2 (COX-2) and non selective COX inhibitors with respect to the extent to which disease activity is improved without self reported, unac...
Eligibility Criteria
Inclusion
- Patients must meet modified New York Classification and/or Assessment of Spondyloarthritis International Society (ASAS) criteria for Classification Criteria for AxSpA
- Ankylosing Spondylitis Disease Activity Score greater than or equal to 2.1.
Exclusion
- Changing background biologic/disease modifying-rheumatic medications within less than 3 months.
- Opioid medication use
- Current or expected pregnancy
- History of cardiovascular disease (previous stroke, myocardial infarction, or percutaneous intervention.
- End stage liver disease
- Chronic Kidney Disease greater than Stage IIIb
Key Trial Info
Start Date :
June 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 11 2023
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04115098
Start Date
June 25 2020
End Date
August 11 2023
Last Update
August 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030